Over the last ten years, a clear trend toward globalization has emerged among drug and medical device companies that are looking overseas to supplement or substitute for U.S. based clinical trials. These countries offer the ample patient populations, faster enrollment and less stringent regulatory environments necessary to initiate and complete effective clinical testing.